| Hazard Information | Back Directory | [Uses]
CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of breast and liver cancer stem cells (CSCs)[1]. | [in vivo]
CWP232228 (100 mg/kg, administered i.p.; daily; 21days for mice bearing 4T1 cell tumors; 60 days for mice bearing MDA-MB-435 cell tumors) results in a significant reduction in tumor volume[1]. | Animal Model: | 7-week-old female Balb/c and NOD/SCID mice bearing 4T1 or MDA-MB-435 cell tumors[1] | | Dosage: | 100 mg/kg | | Administration: | Administered i.p.; daily; 21days for mice bearing 4T1 cell tumors, 60 days for mice bearing MDA-MB-435 cell tumors | | Result: | Treatment resulted in a significant reduction in tumor volume. |
| [References]
[1] Jang GB, et al. Wnt/β-Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells. Cancer Res. 2015 Apr 15;75(8):1691-702. DOI:10.1158/0008-5472.CAN-14-2041
[2] Kim JY, et al. Oncotarget. 2016 Apr 12;7(15):20395-409. CWP232228 targets liver cancer stem cells through Wnt/β-catenin signaling: a novel therapeutic approach for liver cancer treatment. DOI:10.18632/oncotarget.7954 |
|
|